Close Menu

NEW YORK (360Dx) – Chembio Diagnostics announced today that preliminary estimates show its fourth quarter 2018 revenues increased by between 22 percent and 27 percent over the prior-year quarter.

For the three months ended Dec. 31, 2018, the firm reported preliminary revenues of between $7.3 million and $7.6 million.

Chembio, which has a focus on infectious disease diagnostics, said its preliminary revenues for 2018 were between $33.1 million and $33.4 million, an increase of about 38 percent to 39 percent compared to the full-year 2017. 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
Thermo Fisher Scientific

With COVID-19 vaccines rolling out, clinical labs and test developers are preparing for changes in both demand for testing and types of testing for SARS-CoV-2.

Sponsored by

Amid the COVID-19 pandemic, hospitals and intensive care units around the world have been overwhelmed by unprecedented levels of demand. 

Sponsored by
LGC SeraCare Life Sciences

As we pass the one-year anniversary of both the COVID-19 pandemic and the first Emergency Use Authorized SARS-CoV-2 PCR detection assays, there remains significant opportunity for clinical laboratories to advance testing and support improved patient management.

Sponsored by

This webinar will present the details of a COVID-19 saliva screening program that has been implemented at more than 90 different colleges, universities, private schools, and nursing homes across New York state.